Study of the Effect of Single Doses of MK2637 and Dextromethorphan on Cerebral Cortex Excitability (2637-008)

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

15 participants

Study Classification

INTERVENTIONAL

Study Start Date

2009-07-31

Study Completion Date

2009-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study will assess transcranial magnetic stimulation (TMS) as a biomarker and characterize TMS readouts of the activity of MK2637 and dextromethorphan. Resting quantitative electroencephalography(qEEG) readouts are also characterized with MK2637 and dextromethorphan.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Transcranial Current Stimulation as a Treatment for Auditory Hallucinations in Schizophrenia

NCT01963676

Schizophrenia Schizoaffective Disorder Auditory Hallucinations

COMPLETED NA

Does tDCS Change Synaptic Density in the Brains of Patients With Schizophrenia

NCT05435300

Schizophrenia Schizoaffective

RECRUITING

tDCS and Executive Function Training for Schizophrenia

NCT05389345

Schizophrenia Schizophrenia Spectrum Disorder Schizophrenia and Related Disorders

WITHDRAWN NA

MK0557 for the Treatment of Cognitive Impairment in Patients With Schizophrenia (0557-027)

NCT00482430

Paranoid Schizophrenia Schizophrenia

COMPLETED PHASE2

Modulating Human Cortical Plasticity With Transcranial Electrical Stimulation

NCT03114488

Healthy Schizophrenia

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Schizophrenia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

DIAGNOSTIC

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

1

MK2637 120 mg

Group Type EXPERIMENTAL

MK2637

Intervention Type DRUG

Single dose of 120 mg MK2637 capsules in one of five treatment periods.

2

MK2637 50 mg

Group Type EXPERIMENTAL

Comparator: MK2637

Intervention Type DRUG

Single dose of 50 mg MK2637 capsules in one of five treatment periods.

3

Placebo

Group Type PLACEBO_COMPARATOR

Comparator: Placebo

Intervention Type DRUG

Single dose of placebo only in one of five treatment periods.

4

Dextromethorphan 220 mg

Group Type ACTIVE_COMPARATOR

Comparator: Dextromethorphan

Intervention Type DRUG

Single dose of 220 mg dextromethorphan capsules in one of five treatment periods.

5

Dextromethorphan 110 mg

Group Type ACTIVE_COMPARATOR

Comparator: Dextromethorphan

Intervention Type DRUG

Single dose of 110 mg dextromethorphan capsules in one of five treatment periods.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

MK2637

Single dose of 120 mg MK2637 capsules in one of five treatment periods.

Intervention Type DRUG

Comparator: MK2637

Single dose of 50 mg MK2637 capsules in one of five treatment periods.

Intervention Type DRUG

Comparator: Placebo

Single dose of placebo only in one of five treatment periods.

Intervention Type DRUG

Comparator: Dextromethorphan

Single dose of 220 mg dextromethorphan capsules in one of five treatment periods.

Intervention Type DRUG

Comparator: Dextromethorphan

Single dose of 110 mg dextromethorphan capsules in one of five treatment periods.

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Subject is right-handed
* Subject is in good health
* Subject is a nonsmoker

Exclusion Criteria

* Subject works a night shift
* Subject has a history of any illness that might make participation in the study unsafe or confound the study results
* Subject has a history of head injury

Minimum Eligible Age

18 Years

Maximum Eligible Age

40 Years

Eligible Sex

MALE

Accepts Healthy Volunteers

Yes